Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation
Authors:
- Nikhil Shri SahajpalNSNikhil Shri Sahajpal
- Ashis K. MondalAMAshis K. Mondal
- Ashutosh VashishtAVAshutosh Vashisht
- Harmanpreet SinghHSHarmanpreet Singh
- Andy Wing Chun PangAPAndy Wing Chun Pang
- Daniel SaulDSDaniel Saul
- Omar NivinONOmar Nivin
- Benjamin HiltonBHBenjamin Hilton
- Barbara R. DuPontBDBarbara R. DuPont
- Vamsi KotaVKVamsi Kota
- Natasha M. SavageNSNatasha M. Savage
- Alex R. HastieAHAlex R. Hastie
Open Access
Abstract
Homologous recombination deficiency (HRD) is characterized by the inability of a cell to repair the double-stranded breaks using the homologous recombination repair (HRR) pathway. The deficiency of the HRR pathway results in defective DNA repair, leading to genomic instability and tumorigenesis. The presence of HRD has been found to make tumors sensitive to ICL-inducing platinum-based therapies and poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors (PARPi). However, there are no standardized methods to measure and report HRD phenotypes. Herein, we compare optical genome mapping (OGM), chromosomal microarray (CMA), and a 523-gene NGS panel for HRD score calculations. This retrospective study included the analysis of 196 samples, of which 10 were gliomas, 176 were hematological malignancy samples, and 10 were controls. The 10 gliomas were evaluated with both CMA and OGM, and 30 hematological malignancy samples were evaluated with both the NGS panel and OGM. To verify the scores in a larger cohort, 135 cases were evaluated with the NGS panel and 71 cases with OGM. The HRD scores were calculated using a combination of three HRD signatures that included loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale transitions (LST). In the ten glioma cases analyzed with OGM and CMA using the same DNA (to remove any tumor percentage bias), the HRD scores (mean ± SEM) were 13.2 (±4.2) with OGM compared to 3.7 (±1.4) with CMA. In the 30 hematological malignancy cases analyzed with OGM and the 523-gene NGS panel, the HRD scores were 7.6 (±2.2) with OGM compared to 2.6 (±0.8) with the 523-gene NGS panel. OGM detected 70.8% and 66.8% of additional variants that are considered HRD signatures in gliomas and hematological malignancies, respectively. The higher sensitivity of OGM to capture HRD signature variants might enable a more accurate and precise correlation with response to PARPi and platinum-based drugs. This study reveals HRD signatures that are cryptic to current standard of care (SOC) methods used for assessing the HRD phenotype and presents OGM as an attractive alternative with higher resolution and sensitivity to accurately assess the HRD phenotype.Keywords
This publication has 35 references indexed in Scilit:
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerCancer Discovery, 2015
- Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaJNCI: Journal of the National Cancer Institute, 2015
- Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersBreast Cancer Research, 2014
- Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic InhibitionThe Journal of Pharmacology and Experimental Therapeutics, 2014
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging AgentsCancer Discovery, 2012
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor XenograftMolecular Cancer Therapeutics, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaksDNA Repair, 2010